Sacituzumab govitecan-hziy

Sacituzumab tirumotecan, or sac-TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 trial that could help Merck & Co. close a high-stakes gap in its expansive global development program for the Kelun-Biotech-partnered antibody-drug conjugate. Replacing chemotherapy with sac-TMT alongside Merck’s Keytruda slashed the risk of progression or death by 51% in patients with previously untreated nonsquamous NSCLC with a PD-L1 tumor proportion score of less than 1%. Patients who received Keytruda and sac-TMT went a median 15 months without disease progressing, while the Keytruda-chemo arm lasted 5.7 months. The results are being presented at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid and simultaneously published in The New England Journal of Medicine . While overall survival (OS), a secondary endpoint, was immature with only 20% of patients having passed away, the sac-TMT group showed a strong trend toward an improvement of 42%. The estimated one-year survival rate was 77.6% versus 66.4%, respectively. A 51% progression-free survival (PFS) benefit is “clinically compelling,” Marjorie Green, M.D., Merck’s head of oncology global clinical development, said in an interview with Fierce. With multiple Kelun studies showing similar efficacy strengths, “it just gives me more enthusiasm about the asset and what it’s potentially able to do.” Success of the OptiTROP-Lung06 study has a bigger impact than many other phase 3 studies from China, as it offers clues to a key missing piece in Merck’s plan to shore up its PD-1 leadership in the all-important first-line NSCLC setting by replacing conventional chemo with sac-TMT. With nearly 20 global phase 3 trials underway for sac-TMT, Merck has described the TROP2-directed ADC as a “workhorse” product. But it has yet to move the drug into first-line PD-L1-low or -negative nonsquamous NSCLC, the very setting that crowned Keytruda the PD-1 king. Now, with OptiTROP-Lung06 and an earlier OptiTROP-Lung05 win against Keytruda monotherapy in PD-L1-positive NSCLC, Merck appears ever willing to close that gap. “The Kelun OptiTROP-Lung05 [and] 06 gives us a lot of confidence in the target and to target it across the full spectrum of PD-L1,” Merck’s R&D head Dean Li, M.D., Ph.D., said on the company’s second-quarter earnings call back in August. “Yes, we are going to rethink Keynote-189, which is Keytruda plus chemo, and now we have sac-TMT as an ADC, as a next-gen chemo.” Li suggested that Merck will be “very thoughtful” in choosing the immuno-oncology partner for sac-TMT between Keytruda and its PD-1xVEGF candidate, MK-2010. Earlier this month, the New Jersey pharma launched a global phase 2 solid tumor study pairing sac-TMT with MK-2010. The bar for OptiTROP-Lung06 to impress industry watchers is “pretty high,” Leerink Partners analyst Daina Graybosch, Ph.D., said in an interview with Fierce ahead of ESMO. Gilead Sciences’ rival TROP2 ADC, Trodelvy, recently failed in a phase 3 trial in first-line NSCLC. Trodelvy’s Keytruda combo didn’t significantly improve PFS or OS over Keytruda alone in PD-L1-high patients. In a post-hoc subgroup analysis, the combo showed a bigger treatment effect in East Asia, especially China. Based on Trodelvy’s Evoke-03 data, people would assume a deterioration of efficacy from China to global NSCLC trials for a TROP2 ADC and would therefore need to see a large effect size to buy into OptiTROP-Lung06’s potential in a global population. “I think if [the hazard ratio] is below 0.5, people would be like, ‘whoa, okay,’ that sort of swings some enthusiasm back,” Graybosch said. Now, the trial’s PFS hazard ratio has landed at 0.49, with a 95% confidence interval of 0.36 to 0.65. Before seeing the data, Graybosch said investors would be disappointed if the hazard ratio is worse than 0.65. “Not all ADCs are the same,” Green said in response to a question about Evoke-03, a Merck-sponsored study. “They are so different based upon the linker and the payload and the [drug-to-antibody ratio] that you can get directional information about it. And what I saw was activity of TROP2 ADC in non-small cell lung cancer.” Digging deeper into the OptiTROP-Lung06 data. The study’s chemo arm appeared to have slightly underperformed historical experience. In a subgroup analysis of the global Keynote-189 trial, the median PFS for Keytruda plus chemo reached 6.2 months for PD-L1-negative patients. Separately, in a China-only phase 3 trial, Innovent Biologics’ PD-1 drug Tyvyt and chemo registered a 7.3-month median PFS in PD-L1-negative patients. Nevertheless, the sac-TMT combo’s 15-month median PFS still doubled those historical benchmarks. Green described OptiTROP-Lung06’s control arm performance as “very consistent” with the Keynote-189 data. As to OS, even though the data remained early, the Kaplan-Meier curves documenting patients’ survival status show clear separation between the two arms, and the difference widened with no sign so far of closing back up. Subsequent anticancer treatment appears balanced. Among patients who discontinued study treatment, 57% in the sac-TMT arm and 54.1% in the control group received subsequent treatment. Specifically, 1.9% and 17% of patients received an ADC following disease progression. While the objective response rates were similar, at 50.2% and 47.3% between the experimental and control arms, sac-TMT’s responses were deeper and last longer. Green singled out the ability for people to stay on the sac-TMT regimen and enjoy a long duration of response (DoR) as an important factor for the drug’s overall profile. In the study, sac-TMT doubled the median DoR to 13.6 months. In terms of safety, treatment-related adverse events that resulted in death occurred in one patient (0.4%) for sac-TMT due to respiratory failure, versus 1.3% for control. Grade 3 or above treatment-emergent adverse events happened in 47.6% and 60.6% of patients, respectively. Inflammation of the tissue lining the mouth, or stomatitis, a side effect of interest for sac-TMT, happened in 51.1% of patients receiving the ADC-Keytruda combo, including 2.2% at grade 3. In the chemo-Keytruda arm, the rates were 8.4% and 0%, respectively. Even with the two positive China phase 3 trials and Li’s comment indicating a commitment, Merck still hasn’t yet launched that Keynote-189 successor trial for sac-TMT. Graybosch suspected that the New Jersey pharma is waiting for competitor data from Akeso and Summit Therapeutics’ Harmoni-3 readout for their PD-1xVEGF bispecific ivonescimab in a squamous cohort of first-line NSCLC patients, as well as AstraZeneca and Daiichi Sankyo’s Avanzar trial for their TROP2 ADC Datroway, to better inform its development strategy. “You can imagine what is the potential, and the potential is broad, whether it is something like a sac-TMT/Keytruda combination, or is it something with the [PD-1x]VEGF bispecific,” Green said of Merck’s NSCLC portfolio. “So, lots of work ongoing internally, and I’ll just say stay tuned.”

iStock, blueringmedia Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor therapy. Phase 2 results for Marengo Therapeutics’ first-in-class cancer-targeted bispecific antibody invikafusp alfa showed objective responses across eight tumor types, particularly among patients who had been unresponsive to other immunotherapies. The results, which stem from a first-in-human Phase 1/2 study called Start-001 were announced Friday at the European Society for Medical Oncology conference in Madrid, showing tumor shrinkage in 56% of patients with various tumor types. These included breast, colorectal, endometrial, gastrosophageal junction, gastric, head and neck, non-small cell lung and bladder cancers, according to a company release. The study showed an 18% objective response rate and a 60% disease control rate across all patients. Invikafusp alfa, a selective T cell agonist, activates and expands a naturally occurring group of T cells called Vβ, increasing the immune capacity for an antitumor response, Marengo CEO Zhen Su told BioSpace in an email. “We are pioneering this biology to extend the reach of immunotherapy beyond immune checkpoint blockade, including for patients whose cancers have progressed despite these transformative treatments,” Su said, noting the “remarkable success of Keytruda” as well as the mega-blockbuster’s shortcomings, with certain patients forming a resistance to Merck’s drug over time. The 62 patients in the study came in with heavily pretreated tumors that showed a high mutational burden. Patients who had previously received an immune checkpoint blockade drug fared better than those who had never been treated with immunotherapy, showing a 20% objective response rate versus 14%, as well as a 68% disease control rate versus 43%. Cancer ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak A combination of the personalized cancer vaccine intismeran autogene and Merck’s Keytruda just barely cleared analysts’ expectations for recurrence-free survival, leaving questions as to its applicability to tumor types beyond melanoma. October 22, 2026 · 5 min read · Annalee Armstrong Read more In terms of safety, the drug demonstrated manageable tolerability typically seen alongside T cell activation, with some low-grade cytokine release and no neurotoxicity. The study was a proof of concept that activation of Vβ T cells can expand the immune response beyond what PD-1 checkpoint inhibitors like Keytruda can accomplish. “We believe the key is the different mechanism,” Su said. “Immune checkpoint blockade releases the brakes on existing T cells, but that may not be enough when responsive T cells are too few or dysfunctional.” Studies have shown that only 20% to 30% of cancers respond to immune checkpoint blockade drugs, with some types even more resistant than others. Marengo has shown that invikafusp alfa’s bispecific approach is effective across tumor types, including both “cold” cancers like colorectal and “hot” ones like non-small cell lung cancer, Su said. The tissue-agnostic behavior of invikafusp alfa comes from shared immune biology of Vβ-defined T cells that are “part of the normal human immune repertoire,” Su said. He added that “Keytruda’s recent full FDA approval in TMB-high solid tumors reinforces the principle of treating cancers according to shared biology rather than organ of origin.” Targeting cancer this way fuels what could be the next wave of innovation in oncology, Su said. “We see the next wave as precision immunology, enabled by next-generation multispecific technologies that select which immune cell subsets to activate and coordinate the signals they receive,” Su said. Marengo has two FDA fast track designations for invikafusp alfa and plans to take the candidate into late-stage development in 2027, Su said. Meanwhile, the Start-001 trial carries on, with a monotherapy cohort expected to read out in the second half of next year. The company has also combined invikafusp alfa with Gilead Sciences’ breast cancer antibody-drug conjugate (ADC) Trodelvy in patients with metastatic triple-negative and HR-positive, HER2-negative forms of the disease. Early results from a Phase 2 study called Start-002 showed complete responses in heavily pretreated patients, Su said. “Our vision is to establish invikafusp alfa as a precision immunotherapy backbone, bringing fresh T-cell responses together with the tumor-killing activity of standard treatments,” Su said. “These findings support a new dimension in immunotherapy that activates and expands fresh, diverse T-cell responses against cancer.” cancer Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026 At the European Society of Medical Oncology meeting in Madrid this weekend, analysts will be watching for detailed data on Merck and Moderna’s personalized cancer vaccine, Summit and Akeso’s PD-1xVEGF bispecific therapy, and a host of antibody-drug conjugates. October 19, 2026 · 8 min read · Tristan Manalac Read more